Skip Navigation

European Heart Journal 1992 13(7):952-959;
Copyright © 1992 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by POULEUR, H.
Right arrow Articles by ROUSSEAU, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by POULEUR, H.
Right arrow Articles by ROUSSEAU, M. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1992 The European Society of Cardiology

Analysis of the mechanisms underlying the changes in left ventricular filling dynamics during oral nisoldipine therapy in patients with anterior myocardial infarction

H. POULEUR, C. VAN EYLL, O. GURNÉ and M. F. ROUSSEAU

The Department of Physiology and Pharmacology and the Division of Cardiology, University ofLouvain, Medical School Brussels, Belgium

Received 21 August 1991; revised 20 November 1991; .

Correspondence: Hubert Poukur, MD, University of Louvain, avenue Hippocrate 55/5560, 1200 Brussels, Belgium

Abstract

The aim of this study was to clarify the mechanisms responsible for the increase in early filling rate observed during oral nisoldipine therapy in patients with ischaemic left ventricular (LV) dysfunction. For that purpose, the global and regional L Vfunction was analysed before and after 2 months ofdouble-blindmonotherapy with nisoldipine (10 mg twice daily) or a placebo, in 17 patients with a previous anterior myocardial infarction. The baseline LV ejection fraction ranged from 34–51% and no patient had heart failure. Compared to the placebo, nisoldipine significantly lowered LV systolic pressure and end-diastolic pressure ( –3 mmHg vs + 6 with the placebo; P < 0.01) and the L V pressure at the time of mitral opening ( –.20 ± 3.4 mmHg vs + 3.5 ± 3.0; P < 0.01). Despite this reduction in driving pressure, the global L V early peak filling rate improved with nisoldipine only and this improvement was related to a selective increase in expansion rate of the anterior areas, from 1010±360to 1339 ±496 mm2.s–1 (P<0.001). The time to regional peak filling rate (-8%; P<0.01), the asynchrony of diastolic wall motion and the regional ejection fraction (33 ± 10 to 38 ± 12%; P < 0.001) also improved in the anterior areas with nisoldipine but not with the placebo. In contrast, in the inferior, control zones, the regional ejection fraction and filling rate remained unchanged, both when compared to baseline and to the placebo. In conclusion, prolonged nisoldipine therapy had no significant effect on the normal myocardium but improved systolic and diastolic function in hypokinetic areas. The functional improvement in such areas might be related to improved perfusion, to a greater sensitivity to afterload reduction or to an effect of nisoldipine on myocardial calcium handling.

Key Words: Nisoldipine • diastolic function • hibernating myocardium • myocardial infarction


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.